Usana Health Sciences (USNA) Current Deferred Revenue (2011 - 2022)

Usana Health Sciences (USNA) has 10 years of Current Deferred Revenue data on file, last reported at $19.6 million in Q1 2022.

• Current Deferred Revenue for Q1 2022 came in at $19.6 million, up 23.09% year-over-year; the trailing twelve-month figure through Jan 2022 was $19.6 million (up 23.09% YoY), and the FY2022 annual result was $19.6 million, up 23.09% from the prior year.
• Current Deferred Revenue advanced to $19.6 million in Q1 2022 per USNA's latest filing, from $16.0 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $19.6 million in Q1 2022 and troughed at $2.6 million in Q4 2018.
• A 4-year average of $13.0 million and a median of $14.9 million in 2019 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2018 and 2019: Current Deferred Revenue fell 13.61% in 2018, then jumped 423.51% in 2019.
• A 4-year view of Current Deferred Revenue shows it stood at $2.6 million in 2018, then jumped by 423.51% to $13.9 million in 2019, then rose by 15.16% to $16.0 million in 2021, then climbed by 23.09% to $19.6 million in 2022.
• Business Quant data shows USNA's Current Deferred Revenue at $19.6 million in Q1 2022, $16.0 million in Q1 2021, and $13.9 million in Q4 2019.